title: Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.
authors.affiliation: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1550 Orleans Street, Baltimore, MD 21231, USA. rudin@jhmi.edu
authors.forename: Charles M
authors.initials: CM
authors.lastname: Rudin
authors.forename: Kelvin
authors.initials: K
authors.lastname: Hong
authors.forename: Michael
authors.initials: M
authors.lastname: Streit
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics*; D020935:MAP Kinase Signaling System / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation; D010091:Oximes / Q000627:therapeutic use; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; C117307:KRAS protein, human; D010091:Oximes; D011518:Proto-Oncogene Proteins; D048493:Proto-Oncogene Proteins B-raf; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; C561627:dabrafenib